澳门大阳城集团2138网站(官方VIP认证)-最新app下载安装

Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information
Media
Company News
Media Releases
Video
About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Senior Scientific Advisory Board
Media Center
Careers
Company Culture
Join Us
Contact Us
中
中
中

Our Science

 >  Our Science
 >  Pipeline
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications

Pipeline

Name of The Drug
Research Type/Indication
Development Phase
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
HuaTangNing (华堂宁®)
T2D - monotherapy
Launched (China)
T2D - combination therapy with metformin
Launched (China)
HuaTangNing (华堂宁®)
DKD
Launched (China) - Allowances
Combination therapy with DPP4i
Launched (China) - Allowances
Combination therapy with SGLT2i
Launched (China) - Allowances
Fixed dose combinations - dorzagliatin and OADs
T2D
Phase I ready
Next Generation of GKA
Metabolic Diseases
Pre-clinical
Glucokinase compound
Congenital Hyperinsulinism
Pre-clinical
Fructose Kinase Inhibitor
Metabolic Disease
Pre-clinical
mGLUR5 NAM - CNS
PD-LID
Pre-clinical
HuaTangNing (华堂宁®)
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
T2D - monotherapy
Launched (China)
T2D - combination therapy with metformin
Launched (China)
HuaTangNing (华堂宁®)
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
DKD
Launched (China) - Allowances
Combination therapy with DPP4i
Launched (China) - Allowances
Combination therapy with SGLT2i
Launched (China) - Allowances
Fixed dose combinations - dorzagliatin and OADs
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
T2D
Phase I ready
Next Generation of GKA
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
Metabolic Diseases
Pre-clinical
Glucokinase compound
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
Congenital Hyperinsulinism
Pre-clinical
Fructose Kinase Inhibitor
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
Metabolic Disease
Pre-clinical
mGLUR5 NAM - CNS
Preclinical
IND
PhaseⅠ
PhaseⅡ
PhaseⅢ
NDA
Launched
PD-LID
Pre-clinical
About Us
Company Overview
Company History
Leadership Team
Portfolio Advisory Board
Senior Scientific Advisory Board
Partner
Media center
Research & Development
Inovation
Pipeline
Dorzagliatin
mGluR5
Company Publications
Peer Reviewed Publications
Investor Relations
Corporate Governance
Financial Report
Announcements & Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock information
Media
Company News
Media Releases
Video
Careers
Culture
Join Us
Product
HuaTangNing(华堂宁®)
Focus Us
Copyright © 2023  Hua Medicine (Shanghai) Co., Ltd.    互联网药品信息服务资格证书编号: （沪）-非经营-2022-0079
沪ICP备14036654号-1  beiantubiao.png 沪公网安备 31011502013809号
Search